The effect of short-term oral treatment with omeprazole or pantoprazole on the function of polymorphonuclear neutrophils.
Recent studies report an increased risk of enteric infections in patients treated with proton pump inhibitors (PPIs). Polymorphonuclear neutrophils (PMNs) play a key role in host response to bacterial infection. We evaluated the effect of omeprazole and pantoprazole treatment on the PMN function. Fifteen patients were treated with omeprazole 20 mg daily and 15 patients with pantoprazole 40 mg daily for 7 days. Treatment with omeprazole or pantoprazole had no effect on spontaneous nitroblue tetrazolium (NBT) test results. Significant increase in the percentage of phagocytes in the omeprazole group in stimulated NBT test (by 69%) was found. Treatment with omeprazole or pantoprazole had no effect on nitric oxide (NO) concentration in the PMN culture supernatant and serum, cyclic guanosine monophosphate concentration in the PMN culture supernatant and serum, as well as inducible nitric oxide synthase (iNOS) protein expression and p38 mitogen-activated protein kinase activity in PMNs. In conclusion, treatment with PPI has no effect on NO production and p38 mitogen-activated protein kinase activity in PMNs. Interestingly, short-term treatment with omeprazole but not with pantoprazole enhances PMN reactive oxygen species production.
a Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
Maja
M
Kostrzewska
b Department of Immunology, Medical University of Bialystok, Bialystok, Poland.
Marzena
M
Garley
b Department of Immunology, Medical University of Bialystok, Bialystok, Poland.
Wioletta
W
Ratajczak-Wrona
b Department of Immunology, Medical University of Bialystok, Bialystok, Poland.
Ewa
E
Jabłońska
c Department of Public Health, Medical University of Bialystok, Bialystok, Poland.
Jacek
J
Jamiołkowski
a Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
Andrzej
A
Dabrowski
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000494:pharmacology*; D000284:Administration, Oral; D000328:Adult; D006152:Cyclic GMP / Q000378:metabolism; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D008297:Male; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism*; D009569:Nitric Oxide / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D009853:Omeprazole / Q000008:administration & dosage* / Q000494:pharmacology*; D000077402:Pantoprazole; D010750:Phosphoproteins / Q000378:metabolism; D013997:Time Factors; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D010750:Phosphoproteins; D009569:Nitric Oxide; D000077402:Pantoprazole; D052247:Nitric Oxide Synthase Type II; D048051:p38 Mitogen-Activated Protein Kinases; D006152:Cyclic GMP; D009853:Omeprazole
cyclic guanosine monophosphate; guanosine monophosphate cyclique; inhibiteurs de la pompe à proton; neutrophiles polynucléaires; nitric oxide; nitric oxide synthase; nitroblue tetrazolium test; omeprazole; oméprazole; oxyde nitrique; oxyde nitrique synthase; p38 mitogen-activated protein kinase; pantoprazole; polymorphonuclear neutrophils; proton pump inhibitors; protéine kinase activée par l’agent mitogène p38; test au nitrobleu de tétrazolium